The present inventive concept provides non-toxic compositions including ethanol, a polymer, and a polar aprotic solvent and methods of using the same in the field of preservation of plant, human and non-human animal tissue and anatomic pathology disciplines (e.g., surgical pathology, histopathology, cytopathology, forensic pathology). In particular, the compositions provide a safer alternative to aldehyde-based compositions.

A solution for preserving biological samples, includes methyl ethyl ketone peroxide with a percentage by volume between 5% and 25%. There is also a use of a solution for preserving biological samples including methyl ethyl ketone peroxide with a percentage by volume between 5% and 25%. The use includes immersing the sample in the solution.

A solution for preserving biological samples, includes methyl ethyl ketone peroxide with a percentage by volume between 5% and 25%. There is also a use of a solution for preserving biological samples including methyl ethyl ketone peroxide with a percentage by volume between 5% and 25%. The use includes immersing the sample in the solution.

Novel binding molecules, comprising humanized antibodies, fragments, variants, and derivatives thereof, compositions, methods, and kits comprising the same, are described, wherein the binding molecules specifically bind to FXI and FXIa. The binding molecules are capable of binding to and forming an immune complex with the factor XI A2 domain, and thereby disrupting the contact activation molecular complex without affecting hemostatic factor XI activity or activation. The binding molecule of this disclosure is useful in safely inhibiting thrombosis and inflammation without compromising hemostasis. The binding molecules, compositions, methods, and kits provided herein are therefore intended to treat, inter alia, thrombosis- and inflammation-related diseases and conditions. Moreover, polynucleotides encoding the binding molecules of this disclosure, vectors comprising the polynucleotides, and host cells for producing the polynucleotides are provided.

Novel binding molecules, comprising humanized antibodies, fragments, variants, and derivatives thereof, compositions, methods, and kits comprising the same, are described, wherein the binding molecules specifically bind to FXI and FXIa. The binding molecules are capable of binding to and forming an immune complex with the factor XI A2 domain, and thereby disrupting the contact activation molecular complex without affecting hemostatic factor XI activity or activation. The binding molecule of this disclosure is useful in safely inhibiting thrombosis and inflammation without compromising hemostasis. The binding molecules, compositions, methods, and kits provided herein are therefore intended to treat, inter alia, thrombosis- and inflammation-related diseases and conditions. Moreover, polynucleotides encoding the binding molecules of this disclosure, vectors comprising the polynucleotides, and host cells for producing the polynucleotides are provided.

The present invention provides a cyclosporin analog and use thereof, and in particular relates to a compound and use thereof as a mitochondrial protective agent for storing a donated organ. The compound is a compound of formula 1 or a salt thereof, wherein n is 2-5, and R.sub.1 and R.sub.2 are independently selected from H or C.sub.1-C.sub.4 alkyl, wherein R.sub.1 and R.sub.2 can be linked together to form a C.sub.3-C.sub.5 heteroalkyl ring.

##STR00001##

A method that may be used in the imaging of tissues or subjects includes flushing a tissue or subject with a solution, preserving the tissue or subject, and then introducing an imaging contrast agent into the tissue or subject. After these actions, the tissue or subject may be imaged.

A method that may be used in the imaging of tissues or subjects includes flushing a tissue or subject with a solution, preserving the tissue or subject, and then introducing an imaging contrast agent into the tissue or subject. After these actions, the tissue or subject may be imaged.

This invention discloses a method for stabilizing bioactivity of a growth factor, including mixing collagen with a growth factor and freeze drying the mixture to remove water. After this treatment, the bioactivity of the growth factor at room temperature remains stable for at least 7 days.

This invention discloses a method for stabilizing bioactivity of a growth factor, including mixing collagen with a growth factor and freeze drying the mixture to remove water. After this treatment, the bioactivity of the growth factor at room temperature remains stable for at least 7 days.